Related Experiment Video
Updated: Dec 3, 2025
05:23
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
635
Helicobacter pylori eradication improved the Kyoto classification score on endoscopy
Osamu Toyoshima1,2, Toshihiro Nishizawa1,3, Kosuke Sakitani1,4
1Department of Gastroenterology Toyoshima Endoscopy Clinic Tokyo Japan.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology
|October 26, 2020
Summary
Successful Helicobacter pylori eradication significantly decreases the Kyoto classification score. This improvement is mainly due to reduced enlarged folds, nodularity, and diffuse redness observed during endoscopy.
Area of Science:
- Gastroenterology
- Endoscopy
- Infectious Diseases
Background:
- The Kyoto classification, based on endoscopic findings, is used to predict risks associated with Helicobacter pylori infection and gastric cancer.
- The impact of H. pylori eradication on Kyoto classification scores has not been previously established.
Purpose of the Study:
- To evaluate the change in the Kyoto classification score after successful H. pylori eradication.
Main Methods:
- A retrospective analysis was conducted on H. pylori-positive patients who underwent baseline and follow-up esophagogastroduodenoscopy (EGD) after successful eradication.
- The Kyoto score, encompassing atrophy, intestinal metaplasia, enlarged folds, nodularity, and diffuse redness, was calculated before and after treatment.
Main Results:
- Eighty-three patients were included in the study.
- The overall Kyoto score significantly decreased from 3.90 to 2.78 post-eradication (P < 0.001).
- Specific endoscopic findings like enlarged folds, nodularity, and diffuse redness showed significant improvement, while atrophy and intestinal metaplasia scores remained unchanged.
Conclusions:
- H. pylori eradication leads to a significant reduction in the Kyoto classification score.
- The observed decrease in the Kyoto score is primarily attributed to the improvement in endoscopic signs of inflammation such as enlarged folds, nodularity, and diffuse redness.
More Related Videos
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
810
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
810
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
387
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
387
01:26Peptic Ulcer Disease IV: Management
270
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
270
01:23Gastritis III: Clinical Manifestations and Management
895
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
895
01:30Peptic Ulcer Disease I: Introduction
587
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
587
01:28Peptic Ulcer Disease II: Pathophysiology
1.5K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.5K